Glycemic variability may signal retinal changes
-
By
-
Andrea Surnit
-
September 1, 2026
-
3 min
By
Andrea Surnit
September 1, 2026
In the single-arm REFOCUS trial, 46% of patients responded to treatment, with a median response duration of 11.8 months.
September 24, 2026
Phase 1 nonrandomized trial reported no drug-related serious adverse events, but efficacy remains unproven
by Kerri Miller
May 7, 2026